Furthermore, not only did inhibition of LSD1 in ovarian cancer cells, either pharmacologically or genetically, reduce the viability of ovarian cancer cells [31,33], LSD1 knockdown resulted in reduced expression of survivin [33]. Here, BIRC5 is linked to ovarian carcinoma.